This inventor holds 2 USPTO granted patents. Top assignees: University of Pennsylvania, Valorisation-Recherche, Societe En Commandite, Institut De Recherches Cliniques De Montreal. Active years: 2008-2012.
Location History:
- St. Laurent, CA (2008)
- St. Laurent, CA (US) (2012)
Company Filing History:
2 out of 2,655 
2 out of 6 
1 out of 11 Years Active: 2008-2012
Title: The Innovations of Rafick P Sekaly
Introduction
Rafick P Sekaly is a notable inventor based in St. Laurent, CA (US). He has made significant contributions to the field of immunology, particularly in the development of improved vaccines and immunosuppressive therapies. With a total of 2 patents, his work has the potential to impact the treatment of autoimmune diseases and transplant procedures.
Latest Patents
Sekaly's latest patents include "Mutant human CD80 and compositions for and methods of making and using the same." This patent discloses improved vaccines and methods of using the same, as well as immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants. Another significant patent is "Nucleic acids encoding mutant human CD80 and compositions comprising the same," which also focuses on improved vaccines and methods of using the same, along with immunosuppressive compositions for similar medical applications.
Career Highlights
Throughout his career, Rafick P Sekaly has worked with prestigious institutions such as the University of Pennsylvania and Valorisation-Recherche, Société En Commandite. His research has been pivotal in advancing the understanding of immune responses and developing therapeutic strategies.
Collaborations
Some of his notable coworkers include David B Weiner and Michael Agadjanyan. Their collaborative efforts have contributed to the advancements in immunology and vaccine development.
Conclusion
Rafick P Sekaly's innovative work in immunology and his patents reflect his commitment to improving healthcare solutions. His contributions are essential in the ongoing fight against autoimmune diseases and the enhancement of transplant success rates.